Mark Rupar

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 827 citations

Medicine, Hematology, Pharmacology +11

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Xiangdong Liu, Niu Shin, Holly K. Koblish et al. · Blood · 2010 · 559 citations · Full text

Medicine, Immunology, Oncology +14

Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters

Reid Huber, Kathleen Murphy, Bowman Miao et al. · Gene · 2002 · 208 citations

Life Sciences, Molecular Biology, Pharmacology +14

Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells

Phillip C.C. Liu, Xiangdong Liu, Yanlong Li et al. · Cancer Biology & Therapy · 2006 · 186 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu et al. · PLoS ONE · 2020 · 161 citations · Full text

Medicine, Oncology, Pharmacology +14